TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12600796

Group type: COMPARATOR
Intervention: PGE(2) (3, 6, and 12 nmol/ml)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ATP (9000, 18,000, and 36,000 nmol/ml)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of Bk (92 nmol), 5‐HT (156 nmol), His (140 nmol), and PGE(2) (1.95 nmol)
Number of subjects: 36
Study: 11672513

Group type: EXPERIMENTAL
Intervention: Chemotherapy + IFN (COPP: cyclophosphamide, vincristine, prednisone, procarbazine)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Chemotherapy (control group)
Number of subjects: 55
Study: 9097896

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional neuroleptics
Number of subjects: 11
Study: 7989949

Group type: EXPERIMENTAL
Intervention: High-dose interleukin-2 (IL-2) (720,000 IU/kg) every 8 hours
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: High-dose IL-2
Number of subjects: 199
Study: 3068855

Group type: EXPERIMENTAL
Intervention: Chlorproguanil (1.2 mg/kg) and dapsone (1.2 or 2.4 mg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pyrimethamine (1.2 mg/kg) and sulfadoxine (24 mg/kg)
Number of subjects: 48
Study: 29155186

Group type: EXPERIMENTAL
Intervention: Combined MRI-targeted and systematic biopsy
Number of subjects: 459
Study: 28133919

Group type: EXPERIMENTAL
Intervention: Ocriplasmin (125 μg intravitreal injection)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo (intravitreal injection)
Number of subjects: 652
Study: 25976525

Group type: EXPERIMENTAL
Intervention: Solid food introduction before 4 months of age
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Solid food introduction after 6 months of age
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Timing of introduction of hyperallergenic foods
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Asian race
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Maternal history of food allergy
Number of subjects: 149
Study: 22214282

Group type: EXPERIMENTAL
Intervention: 10% KOH solution
Number of subjects: 26

Group type: COMPARATOR
Intervention: SAL + LAC combination
Number of subjects: 26
Study: 21632288

Group type: EXPERIMENTAL
Intervention: PANCREAZE® (pancrelipase)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 18060837

Group type: EXPERIMENTAL
Intervention: Walking exercise (physiotherapy-supervised, moderate intensity walking program)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Walking/breathing exercise (same walking program plus musculoskeletal and respiratory exercises)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard intervention (gentle mobilisation)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Walking exercise and Walking/breathing exercise
Number of subjects: 93
Study: 17074239

Group type: EXPERIMENTAL
Intervention: Intraoperative placement of collagen pieces within the parotid bed during parotidectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional parotidectomy without collagen pieces
Number of subjects: 100
Study: 14765001

Group type: EXPERIMENTAL
Intervention: Pathologic gamblers
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG) results in gamblers
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study: 10830201

Group type: EXPERIMENTAL
Intervention: Regular red cell transfusions (sufficient to reduce the percentage of Hb S gene product from over 90 to less than 30 of total hemoglobin)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 130
Study: 10168261

Group type: EXPERIMENTAL
Intervention: Continued intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lapsed intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continued control
Number of subjects: 0
Study: 31521062

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 13
Study: 29796866

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone (1 cc)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 10 cc (15 μg/ml) oxygen‐ozone (O2‐O3)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study: 26289496

Group type: EXPERIMENTAL
Intervention: Leisure activity program (30 min/3 times/week for 24 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal care activities (Control)
Number of subjects: 42
Study: 24799100

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride and epinephrine at 1:100,000 (Alphacaine; DFL, Brazil)
Number of subjects: 25
Study: 22950711

Group type: EXPERIMENTAL
Intervention: Nimodipine (90 mg/d)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Placebo (90 mg/d)
Number of subjects: 656
Study: 19855334

Group type: EXPERIMENTAL
Intervention: Abdominal exercises 3 days per week
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Abdominal exercises 6 days per week
Number of subjects: 71

Group type: COMPARATOR
Intervention: No abdominal exercises (0 days per week)
Number of subjects: 71
Study: 16368883

Group type: EXPERIMENTAL
Intervention: Large FLT3/ITDs (> or = 40 nucleotides)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Small FLT3/ITDs (< 40 nucleotides)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: No FLT3/ITDs
Number of subjects: 151
Study: 15085500

Group type: EXPERIMENTAL
Intervention: Right lateral decubitus
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 31

Group type: COMPARATOR
Intervention: Left lateral decubitus
Number of subjects: 31

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 31
Study: 11739159

Group type: EXPERIMENTAL
Intervention: Idarubicin + ara-C (IA)
Number of subjects: 1279

Group type: COMPARATOR
Intervention: Fludarabine + ara-C (FA)
Number of subjects: 1279

Group type: COMPARATOR
Intervention: Topotecan + ara-C (TA)
Number of subjects: 1279
Study: 9161812

Group type: EXPERIMENTAL
Intervention: Occult blood screening test (haemoccult IIR) offered by GPs, occupational health doctors, and pharmacists from February 1993 to June 1994.
Number of subjects: 585

Group type: COMPARATOR
Intervention: Intention to take the screening test.
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Sociodemographic and cultural characteristics influencing participation.
Number of subjects: 585
Study: 8107615

Group type: EXPERIMENTAL
Intervention: 3 mg oral oestriol/day for 3 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 3312371

Group type: EXPERIMENTAL
Intervention: Standard care with 1.5 million units streptokinase intravenously
Number of subjects: 11712

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 11712
Study: 29902470

Group type: EXPERIMENTAL
Intervention: Automated Mechanical Peripheral Stimulation (AMPS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: AMPS sham
Number of subjects: 30
Study: 28651442

Group type: EXPERIMENTAL
Intervention: BI 695502 (1 mg/kg)
Number of subjects: 91

Group type: COMPARATOR
Intervention: US-approved Avastin (1 mg/kg)
Number of subjects: 91

Group type: COMPARATOR
Intervention: EU-approved Avastin (1 mg/kg)
Number of subjects: 91
Study: 26813432

Group type: EXPERIMENTAL
Intervention: Chronochemotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 70
Study: 23797426

Group type: EXPERIMENTAL
Intervention: 150 mg of ASA
Number of subjects: 254

Group type: COMPARATOR
Intervention: 75 mg of clopidogrel
Number of subjects: 254
Study: 21102260

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m and carboplatin AUC 6 once every 3 weeks for up to 6 cycles with enzastaurin 1125 or 1200 mg loading dose followed by 500 mg daily until disease progression
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m and carboplatin AUC 6 once every 3 weeks for up to 6 cycles without enzastaurin
Number of subjects: 218

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m and carboplatin AUC 6 once every 3 weeks for up to 6 cycles
Number of subjects: 218
Study: 18511306

Group type: EXPERIMENTAL
Intervention: Stimulant treatment (psychomotor stimulant)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Normal treatment (ADHD group assessed once on normal treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Withdrawal from treatment (ADHD group assessed after withdrawing from treatment for at least one week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (age-matched control subjects)
Number of subjects: 20
Study: 16328487

Group type: EXPERIMENTAL
Intervention: Group I (no DR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group II (mild/moderate DR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group III (moderate/severe nonproliferative DR with laser treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group IV (proliferative DR with laser treatment)
Number of subjects: 40
Study: 14996265

Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia with ketamine and propofol (group P)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Inhalation anaesthesia with sevoflurane by LMA (group S)
Number of subjects: 135
Study: 10890330

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (180 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9131955

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8383769

Group type: EXPERIMENTAL
Intervention: Guava fruit intake (0.5-1.0 kg daily)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 145
Study: 3526853

Group type: EXPERIMENTAL
Intervention: 1.55 mg/kg cibenzoline
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1.80 mg/kg cibenzoline
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 2.2 mg/kg cibenzoline
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 2.6 mg/kg cibenzoline
Number of subjects: 25
Study: 29076234

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support
Number of subjects: 134

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 134
Study: 28470118

Group type: EXPERIMENTAL
Intervention: Diet rich in industrial trans fatty acids
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Diet rich in trans fatty acids from ruminants
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Diet low in trans fatty acids
Number of subjects: 9
Study: 25742207

Group type: EXPERIMENTAL
Intervention: MDDScore (biomarker panel including 9 biomarkers)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: MDDScore (biomarker panel including 9 biomarkers with gender and BMI effects)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overall accuracy of MDDScore
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (nondepressed subjects), n = 86
Number of subjects: 68
Study: 23244401

Group type: EXPERIMENTAL
Intervention: Higher achieving children in 8th grade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low achieving children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher achieving children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fraction magnitude knowledge and whole number division
Number of subjects: 0
Study: 21496312

Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT) at least 30 Gy in 10 fractions commenced within 8 weeks of surgery and/or SRS
Number of subjects: 43

Group type: COMPARATOR
Intervention: Observation following local treatment of intracranial melanoma metastases with surgery and/or SRS
Number of subjects: 43
Study: 18172629

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Follow-up DTI study
Number of subjects: 18
Study: 17117175

Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 1413
Study: 15326260

Group type: EXPERIMENTAL
Intervention: safinamide (SAF) 70 mg/day (range 40 to 90 mg/day)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: safinamide (SAF)
Number of subjects: 101

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 101
Study: 11531679

Group type: EXPERIMENTAL
Intervention: Metaraminol 0.5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 30
Study: 9439354

Group type: EXPERIMENTAL
Intervention: Normal-tension glaucoma with progressive visual field defects
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal-tension glaucoma with stable visual field defects
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Glaucomatous patients with increased intraocular pressure and progressive visual field defects
Number of subjects: 59

Group type: COMPARATOR
Intervention: Glaucomatous patients with increased intraocular pressure and stable visual field defects
Number of subjects: 59
Study: 8315260

Group type: EXPERIMENTAL
Intervention: Alpha-interferon (10 MU/m2, three times weekly for 4 months)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Alpha- and gamma-interferon (2 MU/m2 of gamma-interferon and 10 MU/m2 of alpha-interferon)
Number of subjects: 32
Study: 2894218

Group type: EXPERIMENTAL
Intervention: 10 mg temazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg temazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30794297

Group type: COMPARATOR
Intervention: Asian physicians
Number of subjects: 149775

Group type: EXPERIMENTAL
Intervention: Non-Hispanic white physicians
Number of subjects: 149775

Group type: COMPARATOR
Intervention: Asian patients
Number of subjects: 149775

Group type: EXPERIMENTAL
Intervention: Non-Hispanic white patients
Number of subjects: 149775
Study: 28827725

Group type: EXPERIMENTAL
Intervention: Mutation rate estimation
Number of subjects: 3222

Group type: EXPERIMENTAL
Intervention: Non‐crossover gene conversion rate estimation
Number of subjects: 3222

Group type: EXPERIMENTAL
Intervention: C to T mutations in a 5' CCG 3' to 5' CTG 3' context
Number of subjects: 3222
Study: 26342427

Group type: EXPERIMENTAL
Intervention: Ferroquine 2 mg/kg plus artesunate
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Ferroquine 4 mg/kg plus artesunate
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Ferroquine 6 mg/kg plus artesunate
Number of subjects: 326

Group type: COMPARATOR
Intervention: Ferroquine 4 mg/kg monotherapy
Number of subjects: 326
Study: 23746559

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 21454017

Group type: EXPERIMENTAL
Intervention: Oral contraceptive users (third generation)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Oral contraceptive users (new generation)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All OC users
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All groups (OC users and non-users)
Number of subjects: 43
Study: 19738118

Group type: EXPERIMENTAL
Intervention: OBL-FC (oblimersen plus fludarabine/cyclophosphamide)
Number of subjects: 241

Group type: COMPARATOR
Intervention: FC (fludarabine/cyclophosphamide)
Number of subjects: 241
Study: 16414297

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoid/beta(2)-adrenergic agonist combination drug
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (no treatment) for ex-smokers with COPD
Number of subjects: 4
Study: 15109558

Group type: EXPERIMENTAL
Intervention: Traditional tea preparations of Artemisia annua
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quinine (control)
Number of subjects: 100
Study: 11455223

Group type: EXPERIMENTAL
Intervention: 40 mg dexamethasone premedication
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 20 mg dexamethasone premedication
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 10 mg dexamethasone premedication
Number of subjects: 132
Study: 9734750

Group type: EXPERIMENTAL
Intervention: Omeprazole treatment combined with phylloquinone-restricted diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: Phylloquinone-restricted diet alone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Phylloquinone-restricted diet with omeprazole treatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Phylloquinone-restricted diet
Number of subjects: 13
Study: 8041982

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 31

Group type: COMPARATOR
Intervention: Thiopental-Isoflurane
Number of subjects: 31
Study: 2738549

Group type: EXPERIMENTAL
Intervention: Videotape patient education
Number of subjects: 22

Group type: COMPARATOR
Intervention: Personalized teaching
Number of subjects: 22
Study: 4555981

Group type: EXPERIMENTAL
Intervention: 9-tetrahydrocannabinol administered by smoking
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 9-tetrahydrocannabinol labeled with carbon-14
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subjective symptoms
Number of subjects: 12
Study: 30842392

Group type: EXPERIMENTAL
Intervention: Progressive lumbar stabilization exercises with respiratory resistance
Number of subjects: 43

Group type: COMPARATOR
Intervention: Progressive lumbar stabilization exercises
Number of subjects: 43
Study: 27739325

Group type: EXPERIMENTAL
Intervention: Veliparib with temozolomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Veliparib with carboplatin/paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel with placebo
Number of subjects: 0
Study: 25783381

Group type: EXPERIMENTAL
Intervention: Preoperative nasogastric tube (NGT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No nasogastric tube (no NGT)
Number of subjects: 50
Study: 23490598

Group type: EXPERIMENTAL
Intervention: Reduced-fat diet counseling
Number of subjects: 1781
Study: 22379876

Group type: COMPARATOR
Intervention: Standard intensive therapy of diabetic ketoacidosis
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Intensive therapy for neuroprotection by actovegin
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Reamberin on the background of standard therapy
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Combination of actovegin and reamberin
Number of subjects: 128
Study: 19268494

Group type: EXPERIMENTAL
Intervention: gap200 condition (fixation spot removed, dimmed, expanded, or brightened 200ms before target onset)
Number of subjects: 0

Group type: COMPARATOR
Intervention: gap0 condition (fixation offsets at target onset)
Number of subjects: 0

Group type: COMPARATOR
Intervention: overlap condition (fixation spot stays on)
Number of subjects: 0
Study: 16814082

Group type: EXPERIMENTAL
Intervention: High-dose coenzyme Q(10) (10.0 mg/kg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-dose coenzyme Q(10) (1.0 mg/kg/day)
Number of subjects: 16
Study: 12766622

Group type: EXPERIMENTAL
Intervention: Mecamylamine 7.5 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mecamylamine 15 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (beverage)
Number of subjects: 27
Study: 11967790

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARBs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study: 9327714

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBO) combined with recombinant tissue plasminogen activator (rTPA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: rTPA alone (Control)
Number of subjects: 66
Study: 8447041

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 306
Study: 3914572

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA) to Azathioprine (AZA) and prednisone
Number of subjects: 96
Study: 30940692

Group type: EXPERIMENTAL
Intervention: GSK2292767A single dose (0.05-2 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: GSK2292767A repeat dose (2 mg for 14 days)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: GSK2292767A
Number of subjects: 49
Study: 30144891

Group type: EXPERIMENTAL
Intervention: TB patients
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: HIV-infected TB patients
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: TB treatment
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: Male sex and age
Number of subjects: 1605

Group type: COMPARATOR
Intervention: Non-TB controls
Number of subjects: 1605
Study: 27074126

Group type: EXPERIMENTAL
Intervention: Inositol at 80 mg/kg/d
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Inositol at 40 mg/kg/d
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Inositol at 10 mg/kg/d
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 24703523

Group type: EXPERIMENTAL
Intervention: Hospital plus home exercise programme
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131
Study: 21364152

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 478
Study: 16145740

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg adjuvant to radiotherapy
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Placebo adjuvant to radiotherapy
Number of subjects: 1370
Study: 12514911

Group type: EXPERIMENTAL
Intervention: Uroflowmetry
Number of subjects: 54
Study: 9848529

Group type: EXPERIMENTAL
Intervention: Connective tissue graft including periosteum used as a barrier for guided periodontal tissue regeneration
Number of subjects: 22

Group type: COMPARATOR
Intervention: Open flap debridement (control)
Number of subjects: 22
Study: 7857734

Group type: EXPERIMENTAL
Intervention: Alacepril (37.5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (11 patients)
Number of subjects: 12
Study: 2479052

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (Ateroid)
Number of subjects: 39